Breast Cancer

The research, published in Annals of Internal Medicine, suggests that a reduction in breast cancer deaths can be achieved for Black women while maintaining the same ratio of benefits to harms that occurs when white women undergo screening every other year starting at age 50.

Women newly diagnosed with breast or ovarian cancer who are also carriers of cancer-associated mutations like BRCA1 or BRCA2 are no more likely to die of their tumors than those who don’t have the mutations, according to a new study.

Researchers with the SWOG Cancer Research Network have found that patients with metastatic hormone receptor-positive breast cancer who have low activity levels of the enzyme sTK1 in their blood serum at the start of anti-estrogen treatment live longer and go longer without their disease progressing than patients with high levels.